(188 days)
Not Found
Not Found
No
The device description details a standard immunochromatographic assay based on antigen-antibody complexation and visual interpretation of lines. There is no mention of AI, ML, image processing, or any computational analysis of the results.
No.
The device is for qualitative testing of drugs of abuse in human urine samples, which is a diagnostic purpose, not a therapeutic one.
Yes
The device is intended for qualitative testing for the presence of various drugs and their metabolites in human urine samples, which is a diagnostic purpose.
No
The device description clearly outlines a physical test kit based on immunochromatographic technique using a porous membrane and colored microspheres, which are hardware components.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states that the device is used for "qualitative testing for the presence of Cocaine and it's metabolites... in human urine samples." This involves testing a sample taken from the human body to provide information about a physiological state (the presence of drugs).
- Device Description: The description details a "competitive immunochromatographic technique involving a sample of test urine delivered through a wicking action." This describes a laboratory test performed on a biological sample outside of the body.
- Performance Studies: The performance studies involve testing "human urine samples" and comparing results to other tests, which is typical for validating an IVD.
The core function of the device is to analyze a biological sample (human urine) in vitro (outside the body) to provide diagnostic information (the presence of drugs of abuse). This aligns directly with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Visualine®Cup VI for Drugs of Abuse Test is used for qualitative testing for the presence of Cocaine and it's metabolites at or above 300 ng/ml, Cannabinoids and it's metabolites at or above 50 ng/ml, Morphine and it's metabolites at or above 300 ng/ml, Methamphetamine at or above 1,000 ng/ml, Amphetamine at or above 1,000 ng/ml, Phencyclidine at or above 25 ng/ml, and Benzodiazepines and it's metabolites at or above 300 ng/ml in human urine samples. This test provides only a preliminary screening result; a more specific alternative method should be used to confirm the test result.
Product codes
LDJ, DIO, DJG, DJC, LCM, JXM
Device Description
The Visualine® CupVI for Drugs of Abuse Test is based on the principle of antigen-antibody complexation and is used for the analysis of Cocaine, Cannabinoids, Morphine, Methamphetamine or Amphetamines, Phencyclidine, and Benzodiazepines and their corresponding metabolites in human urine samples. The assay utilizes a competitive immunochromatographic technique involving a sample of test urine delivered through a wicking action as the test panel (holding the porous membrane) is dipped into the urine sample. The drug in the sample competes for the limited antibody sites on the colored microspheres. When an adequate amount of drug is present, it will fill the limited antibody binding sites. This will prevent attachment of the colored microspheres to the probe site on the membrane. Therefore, a positive urine sample will inhibit the formation of precipitin at the probe site. A reference or control line with a secondary antibody reaction is added to the membrane strip to check for proper sample migration on the membrane. This control line should always be present. A negative urine sample will produce two colored lines and a positive urine sample will show only one, the control line.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
This test is intended for use by medical professionals.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Correlation studies between Visualine® V Drugs of Abuse Test and Visualine® II drugs of Abuse Test for Cocaine and it's metabolites, Cannabinoids and it's metabolites, Morphine and it's metabolites, Methamphetamine or Amphetamines and their metabolites, Phencyclidine, and Benzodiazepines and it's metabolites were conducted at Redwood Toxicology Laboratory, Santa Rosa California and at Sun Biomedical Laboratories. The presumptive positive samples were provided by Redwood and assayed on the Hitachi at Redwood followed by testing by the Visualine® V Test, Visualine® Cup VI, and Visualine® II Benzodiazepine and Amphetamine tests. Negative samples consisted of UTAK Laboratories Drug Free Urine pool #5488, and in-house negative urines tested with Sun Biomedical's Visualine® II product for the targete: I drugs of abuse.
Key Metrics
Cocaine:
Positive Agreement: 42/43 (97.7%)
Negative Agreement: 381/381 (>99%)
Overall Agreement: 423/424 (>99%)
Cannabinoids:
Positive Agreement: 46/48 (96%)
Negative Agreement: 376/376 (>99%)
Overall Agreement: 424/424 (>99%)
Morphine:
Positive Agreement: 48/48 (>99%)
Negative Agreement: 375/376 (>99%)
Overall Agreement: 424/424 (>99%)
Methamphetamine:
Positive Agreement: 47/47 (>99%)
Negative Agreement: 377/377 (>99%)
Overall Agreement: 424/424 (>99%)
Phencyclidine:
Positive Agreement: 46/46 (>99%)
Negative Agreement: 378/378 (>99%)
Overall Agreement: 424/424 (>99%)
Benzodiazepines:
Positive Agreement: 55/55 (>99%)
Negative Agreement: 369/369 (>99%)
Overall Agreement: 424/424 (>99%)
Amphetamines:
Positive Agreement: 40/42 (95%)
Negative Agreement: 382/382 (>99%)
Overall Agreement: 424/424 (>99%)
Precision:
Within run and run to run: >99%
Within day and day to day: >99%
Within lot and lot to lot: >99%
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.3870 Cannabinoid test system.
(a)
Identification. A cannabinoid test system is a device intended to measure any of the cannabinoids, hallucinogenic compounds endogenous to marihuana, in serum, plasma, saliva, and urine. Cannabinoid compounds includedelta -9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannabichromene. Measurements obtained by this device are used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use.(b)
Classification. Class II (special controls). A cannabinoid test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
510(k) CONTENT SUMMARY
1. Name of Manufacturer:
Sun Biomedical Laboratories Inc. 604 VPR Center 1001 Lower Landing Road Blackwood, NJ 08012
MAY 0 6 2003
-
- Trade Name; Visualine® Cup VI for Drugs of Abuse Test for Qualitative determination of Cocaine, Cannabinoids, Morphine, Methamphetamine or Amphetamines, Phencyclidine and Benzodiazepines and/or their metabolites 1 Human Urine Samples.
-
- Common Name:
An in-vitro immunoassay, multi-drug test panel using visual color comparison for the detection of Cocaine, Cannabinoids, Morphine, Methamphetamine or Amphetamines, Phencyclidine, and Benzodiazepines in human urine samples.
-
- Regulation # and Classification:
Reg. #862-3170, Class II Device
- Regulation # and Classification:
-
- Test Description:
The Visualine® CupVI for Drugs of Abuse Test is based on the principle of antigen-antibody complexation and is used for the analysis of Cocaine, Cannabinoids, Morphine, Methamphetamine or Amphetamines, Phencyclidine, and Benzodiazepines and their corresponding metabolites in human urine samples. The assay utilizes a competitive immunochromatographic technique involving a sample of test urine delivered through a wicking action as the test panel (holding the porous membrane) is dipped into the urine sample. The drug in the sample competes for the limited antibody sites on the colored microspheres. When an adequate amount of drug is present, it will fill the limited antibody binding sites. This will prevent attachment of the colored microspheres to the probe site on the membrane. Therefore, a positive urine sample will inhibit the formation of precipitin at the probe site.
- Test Description:
A reference or control line with a secondary antibody reaction is added to the membrane strip to check for proper sample migration on the membrane. This control line should always be present. A negative urine sample will produce two colored lines and a positive urine sample will show only one, the control line.
1
6. Comparison of Two Test Systems for Correlation Studies:
The Visualine® Cup VI for Drugs of Abuse Test for Qualitative Determination of Cocaine, Cannabinoids, Morphine, Methamphetamine or Amphetamines, Phencyclidine, and Benzodiazepines assay is correlated to the Sub Biomedical's existing Visualine® V Drugs of Abuse Test and the Visualine® II Benzodiazepine assay and Visualine® II Amphetamine drugs of abuse assay. The following table illustrates the similarities and differences between the assays.
| | Visualine®V Drugs of Abuse
Test for Qualitative
Determination of Cocaine,
Cannabinoids, Morphine,
Methamphetamine, and the
Visualine® II Drugs of Abuse
Assay for Benzodiazepines and
Amphetamines | Visualine® Cup VI for Drugs
of Abuse Test for Qualitative
Determination of Cocaine,
Cannabinoids, Morphine,
Methamphetamine or
Amphetamines, Phencyclidine
and Benzodiazepines |
|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Test Principle | Competitive binding | Competitive binding |
| Sample/Sample Size | Approx. 200 ul urine/test strip | Approx. 200 ul urine/test strip |
| Antibody | Polyclonal and Monoclonal | Polyclonal and Monoclonal |
| Tracer | Ab Colloidal Gold | Ab Colloidal Gold |
| Detection Method | Visual color precipitin formation | Visual color precipitin
formation |
| Test Run Time | 5 minutes | 5 minutes |
| Storage
Requirements | 2-10°C (36-86°F) | 2-10°C (36-86°F) |
| Detection Levels: | | |
| Cocaine | 300 ng/ml | 300 ng/ml |
| Cannabinoids | 50 ng/ml | 50 ng/ml |
| Morphine | 300 ng/ml | 300 ng/ml |
| Methamphetamine | 1000 ng/ml | 1000 ng/ml |
| Phencyclidine | 25 ng/ml | 25 ng/ml |
| Benzodiazepines | 300 ng/ml | 300 ng/ml |
| Amphetamines | 1000 ng/ml | 1000 ng/ml |
| Ancillary Equipment | none | none |
2
-
- Visualine® Cup IV Test Performance Characteristics:
- A. Correlation studies between Visualine® V Drugs of Abuse Test and Visualine® II drugs of Abuse Test for Cocaine and it's metabolites, Cannabinoids and it's metabolites, Morphine and it's metabolites, Methamphetamine or Amphetamines and their metabolites, Phencyclidine, and Benzodiazepines and it's metabolites were conducted at Redwood Toxicology Laboratory, Santa Rosa California and at Sun Biomedical Laboratories. The presumptive positive samples were provided by Redwood and assayed on the Hitachi at Redwood followed by testing by the Visualine® V Test, Visualine® Cup VI, and Visualine® II Benzodiazepine and Amphetamine tests. Negative samples consisted of UTAK Laboratories Drug Free Urine pool #5488, and in-house negative urines tested with Sun Biomedical's Visualine® II product for the targete: I drugs of abuse. The following information represents the correlation between the new Visualine® Cup VI Test and the existing Visualine® V Test, the Visualine® II Benzodiazepine and Amphetamine Tests.
| Cocaine: | Positive Agreement | 42/43 | 97.7% |
|---|---|---|---|
| Negative Agreement | 381/381 | >99% | |
| Overall Agreement | 423/424 | >99% | |
| Cannabinoids | Positive Agreement | 46/48 | 96% |
| Negative Agreement | 376/376 | >99% | |
| Overall Agreement | 424/424 | >99% | |
| Morphine: | Positive Agreement | 48/48 | >99% |
| Negative Agreement | 375/376 | >99% | |
| Overall Agreement | 424/424 | >99% | |
| Methamphetamine: | Positive Agreement | 47/47 | >99% |
| Negative Agreement | 377/377 | >99% | |
| Overall Agreement | 424/424 | >99% | |
| Phencyclidine: | Positive Agreement | 46/46 | >99% |
| Negative Agreement | 378/378 | >99% | |
| Overall Agreement | 424/424 | >99% | |
| Benzodiazepines: | Positive Agreement | 55/55 | >99% |
| Negative Agreement | 369/369 | >99% | |
| Overall Agreement | 424/424 | >99% | |
| Amphetamines | Positive Agreement | 40/42 | 95% |
| Negative Agreement | 382/382 | >99% | |
| Overall Agreement | 424/424 | >99% |
3
-
B. Specificity and Substances Detected:
The individual tests are specific to the labeled drug of abuse or structurally: related compounds. The test detects Cocaine and it's metabolites at 300 ng/ml, Cannabinoids and it's metabolites at 50 ng/ml, Morphine and it's metabolites at 300 ng/ml, Methamphetamine or Amphetamines at 1000 ng/ml. Phencyclidine at 25 ng/ml, and Benzodiazepine (Oxazepam) and it's metabolites at 300 ng/ml. -
C. Precision:
Reproducibility studies for Visualine® Cup VI for Cocaine, Cannabinoids, Morphine, Methamphetamine, Amphetamine, PCP, and Benzodiazepine: indicate:
| Within run and run to run | >99% |
|---|---|
| Within day and day to day | >99% |
| Within lot and lot to lot | >99% |
D. Stability Statement:
Visualine® Cup VI Test stability has been studied. The urine drugs test: are tested every three months and reviewed for acceptance by the Qualit; Control Manager, also every three months, for up to a period of over two years. The acceptance criteria are as follows: A urine specimen containing 0 ng/ml of the analyte of interest will render two distinct magenta lines, one test line and one control line. Samples containing +25% of cutoff analyte levels will show positive results >99% of the tirr >. therefore vielding only the control line. Visualine® Cup VI Tests are stable within their marked expiration date and under the storage conditions as described in the package insert.
4
Image /page/4/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES · USA" are arranged in a circular pattern around the caduceus symbol. The logo is simple and recognizable, and it is often used to represent the U.S. Department of Health & Human Services.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAY 0 6 2003
Ming Sun, Ph.D. Sun Biomedical Laboratories Inc. 604 VPR Center 1001 Lower Landing Road Blackwood, NJ 08012
K023648 Re:
Trade/Device Name: Visualine® Cup VI for Drugs of Abuse Test Regulation Number: 21 CFR 862.3870 Regulation Name: Cannabinoid test system Regulatory Class: Class II Product Code: LDJ; DIO; DJG; DJC; LCM; JXM; Dated: January 30, 2003 Received: March 5, 2003
Dear Dr. Sun:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
5
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
Image /page/6/Picture/0 description: This image shows the logo and contact information for Sun Biomedical Laboratories, Inc. The logo features a black circle with a horizontal line running through it. The text includes the company name, address (604 VPR CENTER, 1001 LOWER LANDING ROAD, BLACKWOOD, NJ 08012), telephone number (856-401-1080), and fax number (856-401-1090).
510 (k) Number: Ko 336 48
DEVICE NAME: Visualine®Cup VI for Drugs of Abuse Test
INDICATIONS FOR USE: The Visualine®Cup VI for Drugs of Abuse Test is used for qualitative testing for the presence of Cocaine and it's metabolites at or above 300 ng/ml, Cannabinoids and it's metabolites at or above 50 ng/ml, Morphine and it's metabolites at or above 300 ng/ml, Methamphetamine at or above 1,000 ng/ml, Amphetamine at or above 1,000 ng/ml, Phencyclidine at or above 25 ng/ml, and Benzodiazepines and it's metabolites at or above 300 ng/ml in human urine samples. This test provides only a preliminary screening result; a more specific alternative method should be used to confirm the test result. This test is intended for use by medical professionals.
Jean Cooger
(Division Sign-Off)
Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number X023648
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
Over-The-Counter--Use
(Optional Format 1-2-96)
OR